Hypoglycemia during rapid methadone dose escalation
Abstract
Objectives: To answer a question whether or not rapid methadone dose increase can be associated with onset of hypoglycemia. This hypothesis is based on the previously reported case reports of hypoglycemia with rapid methadone increase and our clinical experience of a number of cases when symptomatic hypoglycemia during rapid methadone escalation was initially mistaken for methadone overdose. Methods: A retrospective chart review of 59 consecutive opioid-tolerant patients with cancer who received methadone for pain while inpatients in a tertiary cancer center within 1 year was performed. In patients who also had hypoglycemia during the admission, blood glucose levels were analyzed in relationship to the time of methadone titration. Use of steroid, presence of fever, renal insufficiency, and periods of fasting were recorded. Results: Eleven patients (19 percent) had hypoglycemia while receiving methadone, of them two patients had at least two episodes of hypoglycemia. In the 11 cases of documented hypoglycemia, mean methadone dose was nearly doubled (92 percent increase) within 2 days before the onset of hypoglycemia. None of the other recorded factors correlated with glucose level in this group of patients. Conclusions: Present report is the first reported series of patients with hypoglycemic episodes associated with rapid methadone dose escalation. Based on our results, a patient who develops unexplained sweating, palpitations, or lethargy during methadone titration may benefit from blood glucose monitoring. Keywords: pain, methadone, titration, hypoglycemia DOI:10.5055/jom.2013.0144References
Kagansky N, Levy S, Rimon E, et al.: Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Acrh Intern Med. 2003; 163: 1825-1829.
Fung HT, Cheung KH, Lam SK, et al.: A case of unintentional methadone overdose followed by hypoglycemia. Hong Kong J Emerg Med. 2011; 18(4): 239-242.
Maingi S, Moryl N, Andrew F: Symptomatic hypoglycemia due to escalating doses of intravenous methadone. J Pain. 2008; 4(9): 37.
Almirall J, Montoliu J, Torras A, et al.: Propoxyphene-induced hypoglycemia in a patient with chronic renal failure. Nephron. 1989; 53: 273-227.
Leea HT, Tsengb WC, Tarng DC: Recurrent hypoglycemia in a hemodialysis patient related to propoxyphene treatment. J Chin Med Assoc. 2007; 70: 286-288.
Wiederholt IC, Genco M, Foley JM: Recurrent episodes of hypoglycemia induced by propoxyphene. Neurology. 1967; 17: 703-706.
Shah P, Aniszweski J, John F: Propoxyphene-induced hypoglycemia in renal failure. Endocr Pract. 2006; 12: 170-173.
Bullingham RE, McQuay HJ, Dwyer D, et al.: Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis. Br J Pharmacol. 1981; 12: 117-122.
Workgroup on Hypoglycemia, American Diabetes Association: Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28: 1245-1249.
El Daly ES: Effect of intrathecal morphine on blood glucose, glucagon, and tissue glycogen in rats: Comparison with the effect of xantham gum on blood glucose. J Pharm Belg. 1996; 51: 195-199.
Lux F, Brase DA, Dewey WL: Differential effects of subcutaneous and intrathecal administration on blood glucose in mice: Comparison with intracerebroventricular administration. J Pharmacol Exp Ther. 1988; 245: 187-194.
Brase DA, Singha AK, Estrada U, et al.: Hypoglycemia induced by intrathecal opioids in mice: Stereospecificity, drug specificity and effect of fasting. J Pharmacol Exp Ther. 1990; 253: 899-904.
Lux F, Han Yh, Brase DA, et al.: Studies on the mechanism of hypoglycemia induced by intrathecal morphine: Dissociation from behavioral effects, effects of tolerance and depletion of liver glycogen. J Pharmacol Exp Ther. 1989; 249: 688-693.
White CW, Ward CR, Dombrowski DS, et al.: Effect of intrathecal morphine on the fate of glucose. Comparison with effects of insulin and xanthan gum in mice. Biochem Pharmacol. 1993; 45: 459-464.
Brase DA, Ward CR, Tripathi HL, et al.: An insulin-independent mechanism of intrathecal morphine-induced hypoglycemia in mice: Mediation through a central alpha-2 adrenergic pathway. J Pharmacol Exp Ther. 1991; 257: 587-594.
Nolan LJ, Scagnelli LM: Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse. 2007; 42: 1555-1566.
Morabia A, Fabre J, Chee E, et al.: Diet and opiate addiction: A quantitative assessment of the diet of non-institutionalized opiate addicts. Br J Addict. 1989; 84: 173-180.
Bogucka-Bonikowska A, Baran-Furga H, Chmielewska K, et al.: Taste function in methadone-maintained opioid-dependent men. Drug Alcohol Depend. 2002; 68: 113-117.
Mysels DJ, Sullivan MA: The relationship between opioid and sugar intake: Review of evidence and clinical applications. J Opioid Manag. 2010; 6(6): 445-452.
Passariello N, Giugliano D, Quatraro A, et al.: Glucose tolerance and hormonal responses in heroin addicts. A possible role for endogenous opiates in the pathogenesis of non-insulindependent diabetes. Metabolism. 1983; 32: 1163-1165.
Ceriello A, Giugliano D, Passariello N, et al.: Impaired glucose metabolism in heroin and methadone users. Horm Metab Res. 1987; 19: 430-433.
Brambilla F, Guerrini A, Guastalla A, et al.: Glucose-insulin metabolism in heroin addicts. Neuropsychobiology. 1976; 2: 341-349.
Reid RL, Sandler JA, Yen SS: Beta-endorphin stimulates the secretion of insulin and glucagon in diabetes mellitus. Metabolism. 1984; 33(3): 197-199.
Wen T, Peng B, Pintar JE: The MOR-1 opioid receptor regulates glucose homeostasis by modulating insulin secretion. Mol Endocrinol. 2009; 23: 671-678.
Giugliano D: Morphine, opioid peptides, and pancreatic islet function. Diabetes Care. 1984; 7: 92-98.
Cryer PE: The barrier of hypoglycemia in diabetes. Diabetes. 2008; 57: 3169-3176.
Leu J, Cui MH, Shamoon H, et al.: Hypoglycemia-associated autonomic failure is prevented by opioid receptor blockade. J Clin Endocrinol Metab. 2009; 94: 3372-3380.
Nakao K, Nakai Y, Jingami H, et al.: Substantial rise of plasma -endorphin levels after insulin-induced hypoglycemia in human subjects. J Clin Endocrinol Metab. 1979; 49: 838-841.
Poplawski MM, Mastaitis JW, Mobbs CV: Naloxone, but not valsartan, preserves responses to hypoglycemia after antecedent hypoglycemia: Role of metabolic reprogramming in counterregulatory failure. Diabetes. 2011; 60: 39-44.
Caprio S, Gerety G, Tamborlane WV, et al.: Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects. Am J Physiol. 1999; 260: E852-E858.
Vele S, Milman S, Shamoon H, et al.: Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus. J Clin Endocrinol Metab. 2011; 96: 3424-3431.
Milman S, Leu J, Shamoon H, et al.: Opioid receptor blockade prevents exercise-associated autonomic failure in humans. Diabetes. 2012; 61(6): 1609-1615.
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
